MedTrace Logo

Prospective Comparative Validation Study of RUCAM and RECAM

NCT06771011 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 407

Last updated 2025-01-13

No results posted yet for this study

Summary

A total of 407 hospitalized patients with acute liver injury in Beijing Friendship Hospital Affiliated to Capital Medical University were enrolled. The clinical information, biochemical examination, imageological examination (ultrasound, CT, MRI) and liver biopsy pathology of patients with acute liver injury will be collected. The diagnostic efficacy of RECAM and RUCAM in the diagnosis of DILI will be compared, and the consistency of different clinicians in the diagnosis of DILI using RECAM and RUCAM scores will also be compared.

Conditions

  • Drug Induced Liver Injury

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Principal Investigators

  • Xinyan Zhao · Beijing Friendship Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2026-02-01
Completion
2026-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06771011 on ClinicalTrials.gov